Medical isotopes maker Shine Medical Technologies last week created a division to make therapeutic products, saying it plans to first focus on a cancer treatment.
The Janesville, Wis.-based company said its Shine Therapeutics business will begin with the development and commercialization of lutetium-177, an isotope that can be combined with a disease-targeting molecule, for treating neuroendocrine tumors.
Shine said it’s also evaluating other isotopes with therapeutic possibilities. The company named former business development VP Katrina Pitas to lead the new therapeutics business as VP and GM.
“Targeted radiotherapy has the potential to fundamentally change the way cancer patients are treated,” Pitas said in prepared remarks. “But a robust, reliable supply of therapeutic isotopes will be crucial as both the discipline and associated market continue to grow. Our Lu‑177 development program is well underway, and we look forward to bringing high-purity Lu‑177 to market.”
“We are excited to bring our core competencies and technology to serve the rapidly emerging therapeutic market,” added founder & CEO Greg Piefer. “This market is particularly exciting, as it offers very promising therapies for patients who before now had difficult or impossible to treat late stage cancers. The focus of our new division is to ensure cancer patients have a reliable supply chain of isotopes as new drugs are approved.”
Shine said it inked a deal in May with the Czech Academy of Sciences to license the separation technology it plans to use to separate lutetium from enriched ytterbium.